Active surveillance of a national registry revealed small, but significant, absolute differences in complication rates among vascular-closure devices.
The lack of strong post-market surveillance of medical devices continues to vex clinicians and policymakers. Voluntary reporting of safety events has proven to be an inadequate means of monitoring the safety of approved devices. Another approach is prospective, active surveillance using national registries. To test such an approach, investigators used the American College of Cardiology CathPCI registry to obtain data on Mynx, a vascular-closure device that had safety concerns.
The investigators employed an analytic strategy called DELTA (Data Extraction and Longitudinal Trend Analysis), which is designed to conduct multiple risk-adjusted, prospective, safety surveillance analyses over time. The database included 1,822,575 patients who underw…
Reviewing Author
DisclosuresConsultant/Advisory BoardUnited Healthcare; Element Science; Eyedentifeye, F-Prime
EquityHugo Health; Refactor Health; Element Science
Grant/Research SupportPfizer; Agency for Healthcare Research and Quality; Janssen Research and Development, National Institute of Biomedical Imaging and Engineering; National Heart, Lung, and Blood Institute; Centers for Disease Control and Prevention; National Cancer Institute; American Heart Association
DisclosuresConsultant/Advisory BoardUnited Healthcare; Element Science; Eyedentifeye, F-Prime
EquityHugo Health; Refactor Health; Element Science
Grant/Research SupportPfizer; Agency for Healthcare Research and Quality; Janssen Research and Development, National Institute of Biomedical Imaging and Engineering; National Heart, Lung, and Blood Institute; Centers for Disease Control and Prevention; National Cancer Institute; American Heart Association